ESOP (Employee Stock Option Plan)
An Employee Stock Option Plan (ESOP) grants employees the right — but not the obligation — to purchase company shares at a predetermined exercise price after completing a vesting period, regulated for listed companies under SEBI's Share Based Employee Benefits and Sweat Equity (SBEB & SE) Regulations, 2021 and for unlisted companies under the Companies (Share Capital and Debentures) Rules, 2014.
ESOPs are the most common equity-based employee incentive instrument in India and serve the dual purpose of aligning employee interests with shareholder value creation and retaining key talent through multi-year vesting schedules. SEBI consolidated the regulatory framework for listed companies in August 2021 by issuing the SBEB & SE Regulations, which replaced the earlier 2014 SEBI ESOP guidelines and introduced several investor-protective provisions including mandatory compensation committee oversight, valuation disclosure requirements, and stricter lock-in rules for promoter employees.
The lifecycle of an ESOP comprises four stages. At grant, the company's compensation committee approves a specific number of options at an exercise price (typically the market price or a discount to it on the grant date). The vesting schedule specifies when the options become exercisable — commonly in tranches over 2–4 years (e.g., 25% each year over four years) subject to continued employment and sometimes performance milestones. The exercise window is the period after vesting during which employees must exercise their options (typically up to 5–7 years from grant). Settlement can be through the issuance of new shares (which causes dilution) or through secondary market purchases by the trust.
The accounting treatment of ESOPs under Ind AS 102 (Share-based Payment) requires companies to recognise the fair value of granted options as an employee compensation expense over the vesting period, with a corresponding credit to equity. The Black-Scholes model or binomial lattice model is typically used to determine fair value at the grant date. This non-cash expense reduces reported profits and impacts metrics like EBITDA and PAT, which analysts must add back when assessing cash-based earnings quality.
For employees, the tax treatment of ESOPs has two stages: at exercise, the difference between the fair market value (FMV) on the exercise date and the exercise price is treated as a perquisite and taxed as salary income at the applicable slab rate (with TDS deducted by the employer). At sale, any subsequent gain from the exercise price to the sale price is taxed as capital gains — STCG (12.5% for listed shares held less than 12 months after exercise and listing) or LTCG (12.5% for listed shares held more than 12 months).
For investors in listed companies, the ESOP overhang — the total number of unvested and vested-but-unexercised options outstanding — represents a potential dilution of existing shareholders. Monitoring the ESOP dilution as a percentage of total shares outstanding and the exercise price relative to current market price helps quantify this overhang risk, particularly for high-growth companies with large ESOP programmes.